No Data
MSCI Global Small Cap Index adjustment: includes Yuan Ran Agriculture (09858), JF SMARTINVEST (09636) and excludes SOHO CHINA (00410) and others.
On February 12, MSCI announced the results of the February Index review, with adjustments taking effect after the market closes on February 28.
CARsgen's First Enrolled Subject in the THANK-u Plus Platform-Based Allogeneic CAR-T Trial Achieves SCR at Week 4
The first universal CAR-T subject based on the THANK-u Plus platform by Keji Pharmaceutical was evaluated as sCR at the four-week mark.
Shanghai, February 10, 2025 /PRNewswire/ -- Keystone Pharmaceuticals (stock code: 2171.HK), an innovative CAR-T cell therapy company focused primarily on the treatment of hematological malignancies and solid tumors, announced that the first enrolled patient for its universal BCMA CAR-T, developed based on the THANK-u Plus platform, was evaluated at the 28-day visit and showed a stringent complete response (sCR) and minimal residual disease (MRD) negativity. This patient has relapsed/refractory multiple myeloma of the IgA-λ type (R-ISS stage II) and has previously received
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Hong Kong stocks move | KPC Pharmaceuticals-B (02171) surged nearly 14% in early trading. KJC-2219 has launched clinical trials, and CT041 for treating stomach cancer is expected to submit NDA in the first half of the year.
Kejia Pharmaceutical-B (02171) rose nearly 14% in the early session, and as of the time of writing, it is up 12.94%, priced at 11 Hong Kong dollars, with a turnover of 94.1106 million Hong Kong dollars.
Individual Investors Are CARsgen Therapeutics Holdings Limited's (HKG:2171) Biggest Owners and Were Rewarded After Market Cap Rose by HK$510m Last Week
Insiders Could Have Profited By Holding Onto CARsgen Therapeutics Holdings Shares Despite 23% Drop
